Leerink Partnrs Has Bearish Forecast for MAZE Q1 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Leerink Partnrs decreased their Q1 2025 EPS estimates for shares of Maze Therapeutics in a report issued on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.64) per share for the quarter, down from their previous forecast of ($0.58). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($2.55) EPS.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Monday, March 31st. The company reported ($18.32) earnings per share for the quarter, missing the consensus estimate of ($7.60) by ($10.72).

Several other research firms have also commented on MAZE. Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price objective on the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Guggenheim reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 target price on the stock. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.67.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $9.32 on Thursday. Maze Therapeutics has a 52 week low of $9.30 and a 52 week high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.